Proxi Biotech is a biotech company based in Copenhagen, Denmark. We focus on developing next-generation vaccines targeting bacterial infections to combat antimicrobial resistance, which is one of the world’s most pressing medical problems. Using our proprietary BACTOVAC technology we develop safe and highly immunogenic toxoid antigens for superior vaccines. The BACTOVAC technology detoxifies bacterial toxins in a rapid, easy and gentle manner, preserving critical structural epitopes that results in highly immunogenic vaccines. Proxi Biotech’s lead vaccine targeting Clostridioides difficile
infection, a significant unmet need, has demonstrated perfect safety, superiority to benchmark and 100% efficacy and survival in a gold standard challenge model. Several new vaccine candidates, enabled by our BACTOVAC technology, are currently in the pre-clinical development pipeline.